ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Thyroid, Pregnenolone, Progesterone, DHEA, etc
Thyroid, DHEA, Pregnenolone, Progesterone, etc
Low Preoperative Prolactin Levels Predict Non-Organ Confined Prostate Cancer in Clinically Localized Disease
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 138548" data-attributes="member: 13851"><p><strong></strong></p><p><strong>Abstract </strong></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Introduction: </span></strong>To evaluate the association between preoperative serum prolactin (PRL) levels and risk of non-organ confined prostate cancer (PCa) in clinically localized disease.</p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Materials and Methods:</span></strong> From December 2007 to December 2011, 124 patients with clinically localized PCa were retrospectively evaluated. Non-organ confined disease in the surgical specimen was defined according to extra-capsular extension, seminal vesicle invasion, positive surgical margins, and lymph node invasion. The association between clinical factors and serum levels of pituitary-testis hormones with the risk of non-organ confined disease was evaluated. </p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Results: </span></strong>Perioperative factors associated with non-organ confined disease include prostatic-specific antigen (OR 1.144; p = 0.025), proportion of biopsy positive cores (BPC, OR 36.702; p = 0.007), bioptical Gleason Score >6 (OR 2.785; p = 0.034), and PRL (OR 0.756, p < 0.0001). The association was strong for BPC (area under the curve [AUC] 0.704; p < 0.0001) and PRL (AUC 0.299; p < 0.0001). When we dichotomized according to median value, PRL ≤7.7 µg/L was an independent predictor of extraprostatic disease (OR 6.571; p < 0.0001) with fair discrimination power (AUC 0.704; p < 0.0001). </p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Conclusion: </span></strong>Low preoperative PRL levels predict the risk of non-organ confined PCa in clinically localized disease.</p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong>Conclusion </strong></p><p>The involvement of PRL, PRL-R, and its mediators in PCa pathogenesis is debated and unclear. <strong><span style="color: rgb(184, 49, 47)">This is the only study in the recent literature that provides and supports with new theory the evidence that low preoperative serum PRL levels are associated with non-organ confined PCa.</span></strong> T<strong>herefore, the preoperative serum PRL level is a useful tool in planning the patient care strategy, and it should be measured in every patient with PCa.</strong> Molecular biology clinical studies are needed to confirm the biological basis of this association and its implications in improvement of therapies of advanced PCa.</p></blockquote><p></p>
[QUOTE="madman, post: 138548, member: 13851"] [B] Abstract [/B] [B][COLOR=rgb(184, 49, 47)]Introduction: [/COLOR][/B]To evaluate the association between preoperative serum prolactin (PRL) levels and risk of non-organ confined prostate cancer (PCa) in clinically localized disease. [B][COLOR=rgb(184, 49, 47)]Materials and Methods:[/COLOR][/B] From December 2007 to December 2011, 124 patients with clinically localized PCa were retrospectively evaluated. Non-organ confined disease in the surgical specimen was defined according to extra-capsular extension, seminal vesicle invasion, positive surgical margins, and lymph node invasion. The association between clinical factors and serum levels of pituitary-testis hormones with the risk of non-organ confined disease was evaluated. [B][COLOR=rgb(184, 49, 47)]Results: [/COLOR][/B]Perioperative factors associated with non-organ confined disease include prostatic-specific antigen (OR 1.144; p = 0.025), proportion of biopsy positive cores (BPC, OR 36.702; p = 0.007), bioptical Gleason Score >6 (OR 2.785; p = 0.034), and PRL (OR 0.756, p < 0.0001). The association was strong for BPC (area under the curve [AUC] 0.704; p < 0.0001) and PRL (AUC 0.299; p < 0.0001). When we dichotomized according to median value, PRL ≤7.7 µg/L was an independent predictor of extraprostatic disease (OR 6.571; p < 0.0001) with fair discrimination power (AUC 0.704; p < 0.0001). [B][COLOR=rgb(184, 49, 47)]Conclusion: [/COLOR][/B]Low preoperative PRL levels predict the risk of non-organ confined PCa in clinically localized disease. [B]Conclusion [/B] The involvement of PRL, PRL-R, and its mediators in PCa pathogenesis is debated and unclear. [B][COLOR=rgb(184, 49, 47)]This is the only study in the recent literature that provides and supports with new theory the evidence that low preoperative serum PRL levels are associated with non-organ confined PCa.[/COLOR][/B] T[B]herefore, the preoperative serum PRL level is a useful tool in planning the patient care strategy, and it should be measured in every patient with PCa.[/B] Molecular biology clinical studies are needed to confirm the biological basis of this association and its implications in improvement of therapies of advanced PCa. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Thyroid, Pregnenolone, Progesterone, DHEA, etc
Thyroid, DHEA, Pregnenolone, Progesterone, etc
Low Preoperative Prolactin Levels Predict Non-Organ Confined Prostate Cancer in Clinically Localized Disease
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top